# A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Source: https://onco.cc/trials/nct01503502/  
OnCo record `nct01503502` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Flumatinib and Imatinib in Leukaemia, run by Jiangsu HengRui Medicine Co., Ltd., with a status the registry has not verified recently.

## Summary

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia is a phase 2 interventional study registered as NCT01503502 by Jiangsu HengRui Medicine Co., Ltd., with 150 participants planned, started 2011-08 and due to reach its primary completion in 2012-06. Interventions recorded: flumatinib, imatinib. Conditions recorded: Myelogenous Leukemia, Chronic.

Linked to the drug Flumatinib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01503502
- Phase: 2
- Setting: Phase II Study of Flumatinib Versus Imatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT01503502: https://clinicaltrials.gov/study/NCT01503502

## Connected records

- cancers: [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Flumatinib](https://onco.cc/drugs/flumatinib/), [Imatinib](https://onco.cc/drugs/imatinib/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct01503502.json